Equities

Cyclopharm Ltd

Cyclopharm Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)1.37
  • Today's Change0.015 / 1.11%
  • Shares traded4.05k
  • 1 Year change-33.17%
  • Beta0.6499
Data delayed at least 20 minutes, as of Nov 18 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of AUD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments122029
Total Receivables, Net7.907.718.10
Total Inventory108.295.51
Prepaid expenses------
Other current assets, total0.450.570.39
Total current assets303743
Property, plant & equipment, net9.196.606.25
Goodwill, net0.900.870.87
Intangibles, net4.834.574.56
Long term investments--00
Note receivable - long term------
Other long term assets0.03----
Total assets465056
LIABILITIES
Accounts payable3.154.402.17
Accrued expenses----1.02
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.210.210.18
Other current liabilities, total2.871.702.52
Total current liabilities8.677.947.42
Total long term debt4.014.124.33
Total debt4.234.334.51
Deferred income tax--00
Minority interest------
Other liabilities, total0.970.950.92
Total liabilities141313
SHAREHOLDERS EQUITY
Common stock646363
Additional paid-in capital------
Retained earnings (accumulated deficit)(31)(26)(19)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.63)(1.05)(0.92)
Total equity323743
Total liabilities & shareholders' equity465056
Total common shares outstanding949393
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.